Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome

Canadian Journal of Cardiology

Volumn 30, Issue 5, 2014, Pages 534-543

  Small, Heather Yvonne ^a   Montezano, Augusto C ^a   Rios, Francisco J ^a   Savoia, Carmine ^b   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CANCER PATIENT; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); NEOPLASM; OXIDATIVE STRESS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; TUMOR GROWTH; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; INCIDENCE; NEOPLASMS; SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WORLD HEALTH;

EID: 84899631077     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.02.011     Document Type: Review

References (98)

1. Welti J., Loges S., Dimmeler S., Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013, 123:3190-3200.
2. Bautch V.L. VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harb Perspect Med 2012, 2:a006452.
3. Sharma P.S., Sharma R., Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets 2011, 11:624-653.
4. Kieran M.W., Kalluri R., Cho Y.J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2012, 2:a006593.
5. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat Rev Cancer 2013, 13:871-882.
6. Dorff T.B., Pal S.K., Quinn D.I. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol 2014, 7:67-73.
7. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
8. Afonso F.J., Anido U., Fernández-Calvo O., et al. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. Clin Transl Oncol 2013, 15:425-433.
9. Bair S.M., Choueiri T.K., Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013, 23:104-113.
10. Dreyfus B., Kawabata H., Gomez A. Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors. Cancer Epidemiol 2013, 37:191-196.
11. Hayman S.R., Leung N., Grande J.P., Garovic V.D. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012, 14:285-294.
12. Keefe D., Bowen J., Gibson R., et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011, 16:432-444.
13. Caro J., Morales E., Gutierrez E., Ruilope L.M., Praga M. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) 2013, 15:215-216.
14. Machado F.G., Kuriki P.S., Fujihara C.K., et al. Chronic VEGF blockade worsens glomerular injury in the remnant kidney model. PLoS One 2012, 7:e39580.
15. den Deurwaarder E.S., Desar I.M., Steenbergen E.J., et al. Kidney injury during VEGF inhibitor therapy. Neth J Med 2012, 70:267-271.
16. Nagai A., Sado T., Naruse K., et al. Antiangiogenic-induced hypertension: the molecular basis of signaling network. Gynecol Obstet Invest 2012, 73:89-98.
17. Shah D.R., Shah R.R., Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013, 36:413-426.
18. Simons M., Eichmann A. "On-target" cardiac effects of anticancer drugs: lessons from new biology. J Am Coll Cardiol 2012, 60:626-627.
19. Snider K.L., Maitland M.L. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009, 4:67-76.
20. Dienstmann R., Braña I., Rodon J., Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011, 16:1729-1740.
21. Maitland M.L., Lou X.J., Ramirez J., et al. Vascular endothelial growth factor pathway. Pharmacogenet Genomics 2010, 20:346-349.
22. Larsen A.K., Ouaret D., El Ouadrani K., Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011, 131:80-90.
23. Birk D.M., Barbato J., Mureebe L., Chaer R.A. Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovasc Surg 2008, 42:517-530.
24. Lee S., Chen T.T., Barber C.L., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
25. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
26. Hernandez S.L., Banerjee D., Garcia A., et al. Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. Vasc Cell 2013, 5:17.
27. Ferrara N., Gerber H.P., Lecouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
28. Yogi A., O'Connor S.E., Callera G.E., Tostes R.C., Touyz R.M. Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension. Curr Opin Nephrol Hypertens 2010, 19:169-176.
29. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011, 437:169-183.
30. Duval M., Le Boeuf F., Huot J., Gratton J.P. Src-mediated phosphorylation of hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell 2007, 18:4659-4668.
31. Neagoe P.E., Lemieux C., Sirois M.G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005, 280:9904-9912.
32. Oubaha M., Gratton J.P. Phosphorylation of endothelial nitric oxide synthase by atypical PKC zeta contributes to angiopoietin-1-dependent inhibition of VEGF-induced endothelial permeability in vitro. Blood 2009, 114:3343-3351.
33. Zhu C., Qi X., Chen Y., et al. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 2011, 137:1587-1594.
34. Shibuya M. Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13:63-69.
35. Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antiox Redox Signal 2007, 9:731-739.
36. Evangelista A.M., Thompson M.D., Bolotina V.M., Tong X., Cohen R.A. Nox4- and Nox2-dependent oxidant production is required for VEGF-induced SERCA cysteine-674 S-glutathiolation and endothelial cell migration. Free Radic Biol Med 2012, 53:2327-2334.
37. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
38. Saito T., Takeda N., Amiya E., et al. VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing. FEBS Lett 2013, 587:2179-2185.
39. Bates D.O. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010, 87:262-271.
40. Nako H., Kataoka K., Koibuchi N., et al. Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF. Hypertens Res 2012, 35:194-200.
41. Advani A., Kelly D.J., Advani S.L., et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007, 104:14448-14453.
42. Onn A., Herbst R.S. Angiogenesis, metastasis, and lung cancer. An overview. Methods Mol Med 2003, 74:329-348.
43. Gerwins P., Skoldenberg E., Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000, 34:185-194.
44. Maitland M.L., Kasza K.E., Karrison T., et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009, 15:6250-6257.
45. Meadows K.L., Hurwitz H.I. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012, 2:a006577.
46. Humphreys B.D., Atkins M.B. Rapid development of hypertension by sorafenib: toxicity or target?. Clin Cancer Res 2009, 15:5947-5949.
47. Féliz L.R., Tsimberidou A.M. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol 2013, 72:1-12.
48. Robinson E.S., Khankin E.V., Karumanchi S.A., Humphreys B.D. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010, 30:591-601.
49. Niwakawa M., Yamaguchi R., Onozawa Y., et al. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. Cancer Sci 2013, 104:1039-1044.
50. Cohen R.B., Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 2012, 30:2066-2079.
51. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
52. Keizer R.J., Gupta A., Shumaker R., et al. Model-based treatment optimization of a novel VEGFR inhibitor. Br J Clin Pharmacol 2012, 74:315-326.
53. Nazer B., Humphreys B.D., Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011, 124:1687-1691.
54. des Guetz G., Uzzan B., Chouahnia K., Morère J.F. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 2011, 6:197-202.
55. Qi W.X., Shen Z., Tang L.N., Yao Y. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Investig 2014, 34:231-240.
56. Dai F., Shu L., Bian Y., et al. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig 2013, 33:779-788.
57. Hurwitz H.I., Tebbutt N.C., Kabbinavar F., et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013, 18:1004-1012.
58. Goodwin R., Ding K., Seymour L., et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010, 21:2220-2226.
59. Qi W.X., He A.N., Shen Z., Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013, 76:348-357.
60. Azizi M., Chedid A., Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008, 358:95-97.
61. Reimann M., Folprecht G., Haase R., et al. Anti-vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. Exp Transl Stroke Med 2013, 5:7.
62. Sane D.C., Anton L., Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 2004, 7:193-201.
63. Langenberg M.H., Witteveen P.O., Roodhart J., et al. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol 2011, 22:2508-2515.
64. Sahade M., Caparelli F., Hoff P.M. Cediranib: a VEGF receptor tyrosine kinase inhibitor. Future Oncol 2012, 8:775-781.
65. Robinson E.S., Matulonis U.A., Ivy P., et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010, 5:477-483.
66. Lazarus M., Amundson S., Belani R. An association between bevacizumab and recurrent posterior reversible encephalopathy syndrome in a patient presenting with deep vein thrombosis: a case report and review of the literature. Case Rep Oncol Med 2012, 2012:819546.
67. Asaithambi G., Peters B.R., Hurliman E., et al. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. J Clin Pharm Ther 2013, 38:175-176.
68. Tlemsani C., Mir O., Boudou-Rouquette P., et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011, 6:253-258.
69. Lamy C., Oppenheim C., Mas J.L. Posterior reversible encephalopathy syndrome. Handb Clin Neurol 2014, 121:1687-1701.
70. Horsley L., Marti K., Jayson G.C. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol 2012, 8:283-293.
71. Eechoute K., van der Veldt A.A., Oosting S., et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 2012, 92:503-510.
72. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24:1363-1369.
73. Robinson E.S., Khankin E.V., Choueiri T.K., et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010, 56:1131-1136.
74. Ferroni P., Della-Morte D., Palmirotta R., et al. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr Vasc Pharmacol 2012, 10:479-493.
75. Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009, 54:652-658.
76. Mayer E.L., Dallabrida S.M., Rupnick M.A., et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 2011, 58:85-92.
77. Huang D., Ding Y., Li Y., et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010, 70:1053-1062.
78. Kappers M.H., van Esch J.H., Sluiter W., et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010, 56:675-681.
79. Mourad J.J., des Guetz G., Debbabi H., Levy B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008, 19:927-934.
80. Lankhorst S., Kappers M.H., van Esch J.H., Danser A.H., van den Meiracker A.H. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 2014, 20:135-145.
81. Lankhorst S., Kappers M.H., van Esch J.H., Danser A.H., van den Meiracker A.H. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 2013, 31:444-454.
82. Belcik J.T., Qi Y., Kaufmann B.A., et al. Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol 2012, 60:618-625.
83. Mourad J.J., Levy B.I. Mechanisms of antiangiogenic-induced arterial hypertension. Curr Hypertens Rep 2011, 13:289-293.
84. Ushio-Fukai M., Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008, 266:37-52.
85. Kappers M.H., de Beer V.J., Zhou Z., et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012, 59:151-157.
86. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011, 305:487-494.
87. Schutz F.A., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012, 30:871-877.
88. Steingart R.M., Bakris G.L., Chen H.X., et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 2012, 163:156-163.
89. Steingart R.M., Yadav N., Manrique C., Carver J.R., Liu J. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol 2013, 40:690-708.
90. Copur M.S., Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011, 10:151-156.
91. Mir O., Coriat R., Ropert S., et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs 2012, 30:702-707.
92. Nagasawa T., Hye Khan M.A., Imig J.D. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol 2012, 39:454-461.
93. Izzedine H., Massard C., Spano J.P., et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010, 46:439-448.
94. Larochelle P., Kollmannsberger C., Feldman R.D., et al. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol 2012, 19:202-208.
95. Izzedine H., Ederhy S., Goldwasser F., et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807-815.
96. Kruzliak P., Kovacova G., Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis 2013, 16:289-295.
97. Kruzliak P., Novák J., Novák M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens 2014, 27:3-13.
98. Sunshine S.B., Dallabrida S.M., Durand E., et al. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 2012, 109:11306-11311.